| Properties | Information | |
|---|---|---|
| PhytoCAT-ID | PhytoCAT-728 | |
| Phytochemical name or plant extracts | Huanglian extract | |
| PMID | 11093765 | |
| Literature evidence | This resulted in complete inhibition of cdc2 kinase activity and accumulation of cells in G(2). | |
| IUPAC name | NA | |
| Phytochemicals’ class or type of plant extracts | Aqueous extract | |
| Source of phytochemicals or plant Extracts | Coptis chinensis | |
| Geographical availability | China North-Central, China South-Central, China Southeast, Vietnam | |
| Plant parts | Root | |
| Other cancers | Breast cancer, Stomach cancer, Colon cancer | |
| Target gene or protein | Cyclin B1 , cdc2 kinase | |
| Gene or Protein evidence | Therefore, the effect of huanglian on inhibiting tumor growth seems to be mediated by the selective suppression of cyclin B1, which results in the inhibition of cdc2 kinase activity. | |
| Target pathways | NA | |
| IC50 | NA | |
| Potency | Cell growth was completely inhibited after 3 days of continuous drug exposure to 10 μg/ml of herb. | |
| Cell line/ mice model | MCF-7, MDA468, MKN-74 and HCT-116 | |
| Additional information | In newborn infants, huanglian has been shown to increase unconjugated bilirubin in newborns presumably by displacing bilirubin from serum binding proteins. | |
| PubChem ID | NA | |
| Additional PMIDs | NA | |
| Additional sources of information | https://powo.science.kew.org/taxon/urn:lsid:ipni.org:names:710313-1 | |
| Safety | NA |